Anti-emetic Mechanisms of Zingiber Officinale Against Cisplatin Induced Emesis in the Pigeon; Behavioral and Neurochemical Correlates

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2015 Apr 19

PMID 25888212

Citations 18

Authors

Ihsan Ullah

Fazal Subhan

Muhammad Ayaz

Rehmat Shah

Gowhar Ali

Ikram Ul Haq

Sami Ullah

Affiliations

Soon will be listed here.

Abstract

Background: Zingiber officinale (ZO, family Zingiberaceae) has been reported for its antiemetic activity against cancer chemotherapy induced emesis in animal models and in clinics. Current study was designed to investigate ZO for potential usefulness against cisplatin induced vomiting in pigeon and its effects on central and peripheral neurotransmitters involved in the act of vomiting.

Methods: Zingiber officinale acetone fraction (ZO-ActFr) was investigated for attenuation of emesis induced by cisplatin in healthy pigeons. Neurotransmitters DA, 5HT and their metabolites DOPAC, HVA and 5HIAA were analyzed using High Performance Liquid Chromatography system coupled with electrochemical detector in area postrema, brain stem and intestine. Antiemetic effect of ZO-ActFr was correlated with central and intestinal neurotransmitters levels in pigeon.

Results: Cisplatin (7 mg/kg i.v.) induced emesis without lethality upto the observation period. ZO-ActFr (25, 50 & 100 mg/kg) attenuated cisplatin induced emesis ~ 44.18%, 58.13% (P < 0.05) and 27.9%, respectively; the reference drug, metoclopramide (MCP; 30 mg/kg), produced ~ 48.83% reduction (P < 0.05). ZO-ActFr reduced (P < 0.05 - 0.001) 5-hydroxytryptamine (5HT) concentration in the area postrema, brain stem and intestine at 3(rd) hour of cisplatin administration, while at the 18(th) hour ZO treatments attenuated the dopamine upsurge (P < 0.001) caused by cisplatin in the area postrema and 5HT concentration (P < 0.01 - 0.001) in the brain stem and intestine. ZO treatments alone did not altered the basal neurotransmitters and their metabolites in the brain areas and intestine.

Conclusion: The behavioral study verify the antiemetic profile of ZO against cisplatin induced emesis in the pigeon, where central and peripheral neural evidences advocate the involvement of serotonergic mechanism at initial time point (3(rd) hr), while the later time point (18(th) hr) is associated with serotonergic and dopaminergic component in the mediation of its antiemetic effect.

Citing Articles

A re-consideration of neural/receptor mechanisms in chemotherapy-induced nausea and vomiting: current scenario and future perspective.

Ullah I, Ayaz M Pharmacol Rep. 2023; 75(5):1126-1137.

PMID: 37584820 DOI: 10.1007/s43440-023-00514-z.

Comparative Analysis of Active Ingredients and Potential Bioactivities of Essential Oils from and .

Wang Y, Zheng Y, Feng Y, Chen H, Dai S, Wang Y Molecules. 2023; 28(9).

PMID: 37175336 PMC: 10180244. DOI: 10.3390/molecules28093927.

Phytotherapeutic Approach in the Management of Cisplatin Induced Vomiting; Neurochemical Considerations in Pigeon Vomit Model.

Ullah I, Subhan F, Shahid M, Ahmad N, Shah R, Alam J Oxid Med Cell Longev. 2022; 2022:3914408.

PMID: 36148411 PMC: 9489405. DOI: 10.1155/2022/3914408.

Green Nano-Biotechnology: A New Sustainable Paradigm to Control Dengue Infection.

Zohra T, Khalil A, Saeed F, Latif B, Salman M, Ikram A Bioinorg Chem Appl. 2022; 2022:3994340.

PMID: 35979184 PMC: 9377959. DOI: 10.1155/2022/3994340.

Wen Dan Tang: A Potential Jing Fang Decoction for Headache Disorders?.

Pradhan S, Li Y, Gantenbein A, Angst F, Lehmann S, Shaban H Medicines (Basel). 2022; 9(3).

PMID: 35323721 PMC: 8955743. DOI: 10.3390/medicines9030022.

References

Grelot L, Dapzol J, Esteve E, Frugiere A, Bianchi A, Sheldrick R . Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist. Br J Pharmacol. 1998; 124(8):1643-50. PMC: 1565571. DOI: 10.1038/sj.bjp.0702019. View

Diemunsch P, Grelot L . Potential of substance P antagonists as antiemetics. Drugs. 2000; 60(3):533-46. DOI: 10.2165/00003495-200060030-00002. View

Zhang F, Wang L, Yang Z, Liu Z, Yue W . Value of mink vomit model in study of anti-emetic drugs. World J Gastroenterol. 2006; 12(8):1300-2. PMC: 4124448. DOI: 10.3748/wjg.v12.i8.1300. View

Darmani N, Crim J, Janoyan J, Abad J, Ramirez J . A re-evaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res. 2008; 1248:40-58. DOI: 10.1016/j.brainres.2008.10.063. View

Saito R, Takano Y, Kamiya H . Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci. 2003; 91(2):87-94. DOI: 10.1254/jphs.91.87. View

Rauf K, Subhan F, Sewell R . A Bacoside containing Bacopa monnieri extract reduces both morphine hyperactivity plus the elevated striatal dopamine and serotonin turnover. Phytother Res. 2011; 26(5):758-63. DOI: 10.1002/ptr.3631. View

Qian Q, Yue W, Chen W, Yang Z, Liu Z, Wang Y . Effect of gingerol on substance P and NK1 receptor expression in a vomiting model of mink. Chin Med J (Engl). 2010; 123(4):478-84. View

Ernst E, Pittler M . Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000; 84(3):367-71. DOI: 10.1093/oxfordjournals.bja.a013442. View

Wolff M, Leander J . Effects of a 5-HT1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting. Eur J Pharmacol. 1998; 340(2-3):217-20. DOI: 10.1016/s0014-2999(97)01401-5. View

10.

Miller A, Leslie R . The area postrema and vomiting. Front Neuroendocrinol. 1994; 15(4):301-20. DOI: 10.1006/frne.1994.1012. View

11.

Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052.... J Clin Oncol. 2003; 21(22):4112-9. DOI: 10.1200/JCO.2003.01.095. View

12.

Darmani N, Zhao W, Ahmad B . The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew). J Neural Transm (Vienna). 2000; 106(11-12):1045-61. DOI: 10.1007/s007020050222. View

13.

Foss J, Yuan C, Roizen M, Goldberg L . Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. Cancer Chemother Pharmacol. 1998; 42(4):287-91. DOI: 10.1007/s002800050819. View

14.

Minami M, Endo T, Hirafuji M, Hamaue N, Liu Y, Hiroshige T . Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther. 2003; 99(2):149-65. DOI: 10.1016/s0163-7258(03)00057-3. View

15.

Higgins G, Kilpatrick G, Bunce K, Jones B, Tyers M . 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol. 1989; 97(1):247-55. PMC: 1854462. DOI: 10.1111/j.1476-5381.1989.tb11948.x. View

16.

Darmani N . Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology. 2000; 24(2):198-203. DOI: 10.1016/S0893-133X(00)00197-4. View

17.

Yoshikawa T, Yoshida N, Hosoki K . Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret. Eur J Pharmacol. 1996; 301(1-3):143-9. DOI: 10.1016/0014-2999(96)00061-1. View

18.

Duvernoy H, Risold P . The circumventricular organs: an atlas of comparative anatomy and vascularization. Brain Res Rev. 2007; 56(1):119-47. DOI: 10.1016/j.brainresrev.2007.06.002. View

19.

Abdel-Aziz H, Windeck T, Ploch M, Verspohl E . Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 2005; 530(1-2):136-43. DOI: 10.1016/j.ejphar.2005.10.049. View

20.

Navari R . Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013; 73(3):249-62. DOI: 10.1007/s40265-013-0019-1. View